Groupe la Francaise Sells 5,998,400 Shares of DexCom, Inc. $DXCM

Groupe la Francaise trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 98.8% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 75,630 shares of the medical device company’s stock after selling 5,998,400 shares during the period. Groupe la Francaise’s holdings in DexCom were worth $5,098,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. California State Teachers Retirement System increased its holdings in shares of DexCom by 6,567.7% during the 2nd quarter. California State Teachers Retirement System now owns 39,176,552 shares of the medical device company’s stock valued at $2,638,541,000 after acquiring an additional 38,588,991 shares during the last quarter. Norges Bank bought a new stake in DexCom during the fourth quarter worth approximately $483,356,000. AQR Capital Management LLC grew its holdings in DexCom by 597.8% during the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after purchasing an additional 2,658,158 shares during the last quarter. Legal & General Group Plc bought a new position in shares of DexCom in the second quarter valued at approximately $173,237,000. Finally, Deutsche Bank AG acquired a new stake in shares of DexCom in the second quarter worth $164,035,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock opened at $87.90 on Tuesday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a market capitalization of $33.17 billion, a P/E ratio of 34.74, a P/E/G ratio of 1.47 and a beta of 1.42. The stock has a 50 day moving average of $81.60 and a two-hundred day moving average of $72.49. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.48 earnings per share. As a group, equities analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, insider Kevin Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total transaction of $226,669.05. Following the transaction, the executive vice president owned 126,043 shares of the company’s stock, valued at approximately $11,138,419.91. This represents a 1.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,777 shares of company stock valued at $4,950,714 over the last quarter. 0.28% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DXCM. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Barclays reiterated an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Mizuho increased their target price on DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Bank of America dropped their price target on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Argus increased their price objective on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.